1. Li S, Xu D, Zhang C, Xiao C, Yu M, Wang J, Wu W, Lv X, Yuan D, Zhang L, Hong M, Zhou J*, Sun Y*, Ma H*, Zhu Y*. Cinobufagin Directly Targets PDE4D to Disrupt Fibroblast-DendriticCell Crosstalk in Atopic Dermatitis.Advanced Science, 2025, 8:e01670. （中科院一区，IF=14.3）
2. Maosong Hu#, Yuyu Zhu#, Xinyi Tang, Jing Xu, Hanbin Ma, Zhihan Chen, Duo Chen, Wenyuan Wu, Xialin Chen, Rongrong He, Jing Zhou*, Jinao Duan*, Weiguo Chen*, Hongyue Ma*. Self-assembly GSH response based Buforin IIb-Olaparib nanocombination synergistically promotes DNA damage for prostate cancer immunotherapy. Chemical Engineering Journal, 2025, 508:160862.（中科院一区，IF=13.5）3. Yuyu Zhu#*, Lixin Zhao#, Wei Yan#, Hongyue Ma#, Wanjun Zhao, Jiao Qu, Wei Zheng, Chenyang Zhang, Haojie Du, Meng Yu, Ning Wan, Hui Ye, Yicheng Xie, Bowen Ke, Qiang Xu, Haiyan Sun*, Yang Sun*, Zijun Ouyang*. Celastrol directly targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression. Acta Pharmaceutica Sinica B, 2025,15(2):876-891.（中科院一区，IF=14.6）
4. Xu DH, Lv X, Yu M, Tan A, Wang JJ, Tang XY, Li MY, Wu WW, Zhu YY*, Zhou J*, Ma HY*. Discovery of toad-derived peptide analogue targeting ARF6 to induce immunogenic cell death for immunotherapy of hepatocellular carcinoma. Journal of Pharmaceutical Analysis. 2025,15(3): 101038（中科院一区，IF=8.9）
5. Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, Kong L, Xu Q*, Ma H*, Sun Y*. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. Acta Pharmaceutica Sinica B, 2022, 12(11): 4011-4039.（中科院一区，IF=14.6）
